Predictive Value of Expression and Promoter Hypermethylation of XAF1 in Hepatitis B Virus-Associated Hepatocellular Carcinoma Treated with Transplantation

[1]  Feng Zhang,et al.  MMP2 promoter polymorphism (C‐1306T) and risk of recurrence in patients with hepatocellular carcinoma after transplantation , 2008, Clinical genetics.

[2]  Y. Jeng,et al.  Differential DNA methylation associated with hepatitis B virus infection in hepatocellular carcinoma , 2007, International journal of cancer.

[3]  K. Miller,et al.  Gene expression and promoter methylation of the XIAP-associated Factor 1 in renal cell carcinomas: correlations with pathology and outcome. , 2007, Cancer letters.

[4]  Joong-Won Park,et al.  Association between vascular endothelial growth factor gene polymorphisms and survival in hepatocellular carcinoma patients , 2007, Hepatology.

[5]  T. Liang,et al.  MDR1 gene polymorphisms and risk of recurrence in patients With hepatocellular carcinoma after liver transplantation , 2007, Journal of surgical oncology.

[6]  M. Sata,et al.  X-linked inhibitor of apoptosis (XIAP) and XIAP-associated factor-1 expressions and their relationship to apoptosis in human hepatocellular carcinoma and non-cancerous liver tissues. , 2007, Oncology reports.

[7]  Kil Yeon Lee,et al.  Frequent alteration of XAF1 in human colorectal cancers: implication for tumor cell resistance to apoptotic stresses. , 2007, Gastroenterology.

[8]  Kenichi Sugihara,et al.  Effect of Combined Therapy With Low-Dose 5-Aza-2′-Deoxycytidine and Irinotecan on Colon Cancer Cell Line HCT-15 , 2007, Annals of Surgical Oncology.

[9]  Rong Li,et al.  CpG Island Methylator Phenotype Association with Elevated Serum α-Fetoprotein Level in Hepatocellular Carcinoma , 2007, Clinical Cancer Research.

[10]  Hui Zeng,et al.  Correlation between the single-site CpG methylation and expression silencing of the XAF1 gene in human gastric and colon cancers. , 2006, Gastroenterology.

[11]  Li Wang,et al.  Frequent Epigenetic Inactivation of Spleen Tyrosine Kinase Gene in Human Hepatocellular Carcinoma , 2006, Clinical Cancer Research.

[12]  T. Pfammatter,et al.  Transarterial Chemoembolization as a Bridge to Liver Transplantation for Hepatocellular Carcinoma: An Evidence‐Based Analysis , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[13]  W. Chapman,et al.  Pre-liver transplantation locoregional adjuvant therapy for hepatocellular carcinoma as a strategy to improve longterm survival. , 2006, Journal of the American College of Surgeons.

[14]  S. Chi,et al.  Promoter CpG hypermethylation and downregulation of XAF1 expression in human urogenital malignancies: implication for attenuated p53 response to apoptotic stresses , 2006, Oncogene.

[15]  J. Xu,et al.  CD147, MMP-2, MMP-9 and MVD-CD34 are significant predictors of recurrence after liver transplantation in hepatocellular carcinoma patients , 2006, Cancer biology & therapy.

[16]  P. Laird,et al.  CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer , 2006, Nature Genetics.

[17]  P. Ekman,et al.  Switch to full‐length of XAF1 mRNA expression in prostate cancer cells by the DNA methylation inhibitor , 2006, International journal of cancer.

[18]  M. Yuen,et al.  All-trans retinoic acid induces XAF1 expression through an interferon regulatory factor-1 element in colon cancer. , 2006, Gastroenterology.

[19]  M. Qiao,et al.  Low expression of XIAP-associated factor 1 in human colorectal cancers. , 2005, Chinese journal of digestive diseases.

[20]  M. Martinka,et al.  XAF1 expression is significantly reduced in human melanoma. , 2004, The Journal of investigative dermatology.

[21]  J. Geschwind,et al.  The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Kyucheol Cho,et al.  Hypermethylation of XIAP-associated factor 1, a putative tumor suppressor gene from the 17p13.2 locus, in human gastric adenocarcinomas. , 2003, Cancer research.

[23]  J. Herman,et al.  Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. , 2003, The American journal of pathology.

[24]  M. Kew.  Epidemiology of hepatocellular carcinoma. , 2002, Toxicology.

[25]  S. Thorgeirsson,et al.  Molecular pathogenesis of human hepatocellular carcinoma , 2002, Nature Genetics.

[26]  M. Feitelson,et al.  Genetic mechanisms of hepatocarcinogenesis , 2002, Oncogene.

[27]  R. Korneluk,et al.  Expression and genetic analysis of XIAP-associated factor 1 (XAF1) in cancer cell lines. , 2000, Genomics.

[28]  P. Laird,et al.  MethyLight: a high-throughput assay to measure DNA methylation. , 2000, Nucleic acids research.

[29]  A. Hall,et al.  Primary prevention of hepatocellular carcinoma in developing countries. , 2000, Mutation research.

[30]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Stefan Böhringer,et al.  A novel real-time PCR assay for quantitative analysis of methylated alleles (QAMA): analysis of the retinoblastoma locus. , 2004, Nucleic acids research.

[32]  P. Laird,et al.  Adenocarcinoma Epigenetic Patterns in the Progression of Esophageal Updated Version , 2001 .

[33]  F. X. Bosch,et al.  Epidemiology of Primary Liver Cancer , 1999, Seminars in liver disease.